Corrêa Nilton Lavatori, de Sá Lidia Vasconcellos, de Mello Rossana Corbo Ramalho
1 Department of Nuclear Medicine, State Institute of Diabetes and Endocrinology (IEDE) , Rio de Janeiro, Brazil .
2 Department of Medical Physics, Institute of Radiation Protection and Dosimetry , National Nuclear Energy Commission (IRD/CNEN), Rio de Janeiro, Brazil .
Thyroid. 2017 Feb;27(2):261-270. doi: 10.1089/thy.2016.0266. Epub 2016 Nov 21.
An increase in the incidence of second primary cancers is the late effect of greatest concern that could occur in differentiated thyroid carcinoma (DTC) patients treated with radioactive iodine (RAI). The decision to treat a patient with RAI should therefore incorporate a careful risk-benefit analysis. The objective of this work was to adapt the risk-estimation models developed by the Biological Effects of Ionizing Radiation Committee to local epidemiological characteristics in order to assess the carcinogenesis risk from radiation in a population of Brazilian DTC patients treated with RAI. Absorbed radiation doses in critical organs were also estimated to determine whether they exceeded the thresholds for deterministic effects.
A total of 416 DTC patients treated with RAI were retrospectively studied. Four organs were selected for absorbed dose estimation and subsequent calculation of carcinogenic risk: the kidney, stomach, salivary glands, and bone marrow. Absorbed doses were calculated by dose factors (absorbed dose per unit activity administered) previously established and based on standard human models. The lifetime attributable risk (LAR) of incidence of cancer as a function of age, sex, and organ-specific dose was estimated, relating it to the activity of RAI administered in the initial treatment.
The salivary glands received the greatest absorbed doses of radiation, followed by the stomach, kidney, and bone marrow. None of these, however, surpassed the threshold for deterministic effects for a single administration of RAI. Younger patients received the same level of absorbed dose in the critical organs as older patients did. The lifetime attributable risk for stomach cancer incidence was by far the highest, followed in descending order by salivary-gland cancer, leukemia, and kidney cancer.
RAI in a single administration is safe in terms of deterministic effects because even high-administered activities do not result in absorbed doses that exceed the thresholds for significant tissue reactions. The Biological Effects of Ionizing Radiation Committee mathematical models are a practical method of quantifying the risks of a second primary cancer, demonstrating a marked decrease in risk for younger patients with the administration of lower RAI activities and suggesting that only the smallest activities necessary to promote an effective ablation should be administered in low-risk DTC patients.
第二原发性癌症发病率的增加是接受放射性碘(RAI)治疗的分化型甲状腺癌(DTC)患者最值得关注的晚期效应。因此,决定对患者进行RAI治疗时应进行仔细的风险效益分析。本研究的目的是根据电离辐射生物学效应委员会开发的风险评估模型,结合当地的流行病学特征,评估巴西接受RAI治疗的DTC患者群体因辐射导致的致癌风险。同时,还估算了关键器官的吸收辐射剂量,以确定是否超过确定性效应的阈值。
对416例接受RAI治疗的DTC患者进行回顾性研究。选择了四个器官进行吸收剂量估算及后续致癌风险计算:肾脏、胃、唾液腺和骨髓。吸收剂量通过先前基于标准人体模型确定的剂量因子(每单位给药活度的吸收剂量)计算得出。根据年龄、性别和器官特异性剂量估算癌症发病的终身归因风险(LAR),并将其与初始治疗时给予的RAI活度相关联。
唾液腺接受的辐射吸收剂量最大,其次是胃、肾脏和骨髓。然而,单次给予RAI时,这些器官的吸收剂量均未超过确定性效应的阈值。年轻患者关键器官的吸收剂量水平与老年患者相同。胃癌发病的终身归因风险最高,其次依次为唾液腺癌、白血病和肾癌。
就确定性效应而言,单次给予RAI是安全的,因为即使给予高活度的RAI,吸收剂量也不会超过显著组织反应的阈值。电离辐射生物学效应委员会的数学模型是量化第二原发性癌症风险的实用方法,表明给予较低活度的RAI时,年轻患者的风险显著降低,这表明在低风险DTC患者中,应仅给予促进有效消融所需的最小活度。